Siponimod and CYP2C9 Allele Prevalence Among Blacks
- PMID: 31701536
- DOI: 10.1002/jcph.1546
Siponimod and CYP2C9 Allele Prevalence Among Blacks
References
-
- Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet (London, England). 2018;391:1263-1273.
-
- Mayzent (siponimod) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2019.
-
- Dumitrescu L, Constantinescu CS, Tanasescu R. Siponimod for the treatment of secondary progressive multiple sclerosis. Expert Opin Pharmacother. 2019;20:143-150.
-
- Dilokthornsakul P, Valuck RJ, Nair KV, Corboy JR, Allen RR, Campbell JD. Multiple sclerosis prevalence in the United States commercially insured population. Neurology. 2016;86:1014-1021.
-
- Langer-Gould A, Brara SM, Beaber BE, Zhang JL. Incidence of multiple sclerosis in multiple racial and ethnic groups. Neurology. 2013;80:1734-1739.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical